Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Heron Therapeutics Q2 EPS $(0.02) Misses $(0.01) Estimate, Sales $37.200M Miss $38.075M Estimate

Author: Benzinga Newsdesk | August 08, 2025 06:53am
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 53.85 percent. This is a 66.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $37.200 million which missed the analyst consensus estimate of $38.075 million by 2.30 percent. This is a 3.26 percent increase over sales of $36.024 million the same period last year.

Posted In: HRTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist